APO RESEARCH · REPORT
mRNA Vaccines & Therapeutics
mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.
Product & engineering
Understand the product.
mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.
Selected research
Industry Research
mRNA Vaccines & Therapeutics Industry Research Report 2026
Market perspective
mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.
Global core mRNA vaccines & therapeutics manufacturers include Moderna Therapeutics, CureVac etc. The top 3 companies hold a share about 65%. Europe is the largest market, with a share about 10%, followed by Asia Pacific and North America.
Report Scope
Read the full market overview
This report quantifies the global mRNA Vaccines & Therapeutics market in terms of revenue (US$ million) and, where applicable, sales volume (M Doses), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/M Doses) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
mRNA Vaccines & Therapeutics Market by Company
Moderna Therapeutics
CureVac
Translate Bio
BioNTech
Sangamo Therapeutics
Argos Therapeutics
In-Cell-Art
eTheRNA
Ethris
Tiba Biotechnology
mRNA Vaccines & Therapeutics Segment by Type
Infectious Disease Vaccines
Cancer Vaccines
mRNA Vaccines & Therapeutics Segment by Application
Infectious Disease
Cancer
mRNA Vaccines & Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global mRNA Vaccines & Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of mRNA Vaccines & Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of mRNA Vaccines & Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of mRNA Vaccines & Therapeutics manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of mRNA Vaccines & Therapeutics by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of mRNA Vaccines & Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Infectious Disease Vaccines
- Cancer Vaccines
Applications
- Infectious Disease
- Cancer
Companies covered
- Moderna Therapeutics
- CureVac
- Translate Bio
- BioNTech
- Sangamo Therapeutics
- Argos Therapeutics
- In-Cell-Art
- eTheRNA
- Ethris
- Tiba Biotechnology
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global mRNA Vaccines & Therapeutics Market Size (2021-2032)
- 2.2.2 Global mRNA Vaccines & Therapeutics Sales (2021-2032)
- 2.2.3 Global mRNA Vaccines & Therapeutics Market Average Price (2021-2032)
- 2.3 mRNA Vaccines & Therapeutics by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Infectious Disease Vaccines
- 2.3.3 Cancer Vaccines
- 2.4 mRNA Vaccines & Therapeutics by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Infectious Disease
- 2.4.3 Cancer
3 Market Competitive Landscape by Manufacturers
- 3.1 Global mRNA Vaccines & Therapeutics Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global mRNA Vaccines & Therapeutics Sales (M Doses) of Manufacturers (2021-2026)
- 3.3 Global mRNA Vaccines & Therapeutics Revenue of Manufacturers (2021-2026)
- 3.4 Global mRNA Vaccines & Therapeutics Average Price by Manufacturers (2021-2026)
- 3.5 Global mRNA Vaccines & Therapeutics Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of mRNA Vaccines & Therapeutics, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of mRNA Vaccines & Therapeutics, Product Type & Application
- 3.8 Global Manufacturers of mRNA Vaccines & Therapeutics, Established Date
- 3.9 Global mRNA Vaccines & Therapeutics Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Moderna Therapeutics
- 4.1.1 Moderna Therapeutics Company Information
- 4.1.2 Moderna Therapeutics Business Overview
- 4.1.3 Moderna Therapeutics mRNA Vaccines & Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Moderna Therapeutics mRNA Vaccines & Therapeutics Product Portfolio
- 4.1.5 Moderna Therapeutics Recent Developments
- 4.2 CureVac
- 4.2.1 CureVac Company Information
- 4.2.2 CureVac Business Overview
- 4.2.3 CureVac mRNA Vaccines & Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 CureVac mRNA Vaccines & Therapeutics Product Portfolio
- 4.2.5 CureVac Recent Developments
- 4.3 Translate Bio
- 4.3.1 Translate Bio Company Information
- 4.3.2 Translate Bio Business Overview
- 4.3.3 Translate Bio mRNA Vaccines & Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Translate Bio mRNA Vaccines & Therapeutics Product Portfolio
- 4.3.5 Translate Bio Recent Developments
- 4.4 BioNTech
- 4.4.1 BioNTech Company Information
- 4.4.2 BioNTech Business Overview
- 4.4.3 BioNTech mRNA Vaccines & Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 BioNTech mRNA Vaccines & Therapeutics Product Portfolio
- 4.4.5 BioNTech Recent Developments
- 4.5 Sangamo Therapeutics
- 4.5.1 Sangamo Therapeutics Company Information
- 4.5.2 Sangamo Therapeutics Business Overview
- 4.5.3 Sangamo Therapeutics mRNA Vaccines & Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Sangamo Therapeutics mRNA Vaccines & Therapeutics Product Portfolio
- 4.5.5 Sangamo Therapeutics Recent Developments
- 4.6 Argos Therapeutics
- 4.6.1 Argos Therapeutics Company Information
- 4.6.2 Argos Therapeutics Business Overview
- 4.6.3 Argos Therapeutics mRNA Vaccines & Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Argos Therapeutics mRNA Vaccines & Therapeutics Product Portfolio
- 4.6.5 Argos Therapeutics Recent Developments
- 4.7 In-Cell-Art
- 4.7.1 In-Cell-Art Company Information
- 4.7.2 In-Cell-Art Business Overview
- 4.7.3 In-Cell-Art mRNA Vaccines & Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 In-Cell-Art mRNA Vaccines & Therapeutics Product Portfolio
- 4.7.5 In-Cell-Art Recent Developments
- 4.8 eTheRNA
- 4.8.1 eTheRNA Company Information
- 4.8.2 eTheRNA Business Overview
- 4.8.3 eTheRNA mRNA Vaccines & Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 eTheRNA mRNA Vaccines & Therapeutics Product Portfolio
- 4.8.5 eTheRNA Recent Developments
- 4.9 Ethris
- 4.9.1 Ethris Company Information
- 4.9.2 Ethris Business Overview
- 4.9.3 Ethris mRNA Vaccines & Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Ethris mRNA Vaccines & Therapeutics Product Portfolio
- 4.9.5 Ethris Recent Developments
- 4.10 Tiba Biotechnology
- 4.10.1 Tiba Biotechnology Company Information
- 4.10.2 Tiba Biotechnology Business Overview
- 4.10.3 Tiba Biotechnology mRNA Vaccines & Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Tiba Biotechnology mRNA Vaccines & Therapeutics Product Portfolio
- 4.10.5 Tiba Biotechnology Recent Developments
5 Global mRNA Vaccines & Therapeutics Market Scenario by Region
- 5.1 Global mRNA Vaccines & Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global mRNA Vaccines & Therapeutics Sales by Region: 2021-2032
- 5.2.1 Global mRNA Vaccines & Therapeutics Sales by Region: 2021-2026
- 5.2.2 Global mRNA Vaccines & Therapeutics Sales by Region: 2027-2032
- 5.3 Global mRNA Vaccines & Therapeutics Revenue by Region: 2021-2032
- 5.3.1 Global mRNA Vaccines & Therapeutics Revenue by Region: 2021-2026
- 5.3.2 Global mRNA Vaccines & Therapeutics Revenue by Region: 2027-2032
- 5.4 North America mRNA Vaccines & Therapeutics Market Facts & Figures by Country
- 5.4.1 North America mRNA Vaccines & Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America mRNA Vaccines & Therapeutics Sales by Country (2021-2032)
- 5.4.3 North America mRNA Vaccines & Therapeutics Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe mRNA Vaccines & Therapeutics Market Facts & Figures by Country
- 5.5.1 Europe mRNA Vaccines & Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe mRNA Vaccines & Therapeutics Sales by Country (2021-2032)
- 5.5.3 Europe mRNA Vaccines & Therapeutics Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific mRNA Vaccines & Therapeutics Market Facts & Figures by Country
- 5.6.1 Asia Pacific mRNA Vaccines & Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific mRNA Vaccines & Therapeutics Sales by Country (2021-2032)
- 5.6.3 Asia Pacific mRNA Vaccines & Therapeutics Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America mRNA Vaccines & Therapeutics Market Facts & Figures by Country
- 5.7.1 South America mRNA Vaccines & Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America mRNA Vaccines & Therapeutics Sales by Country (2021-2032)
- 5.7.3 South America mRNA Vaccines & Therapeutics Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa mRNA Vaccines & Therapeutics Market Facts & Figures by Country
- 5.8.1 Middle East and Africa mRNA Vaccines & Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa mRNA Vaccines & Therapeutics Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa mRNA Vaccines & Therapeutics Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global mRNA Vaccines & Therapeutics Sales by Type (2021-2032)
- 6.1.1 Global mRNA Vaccines & Therapeutics Sales by Type (2021-2032) & (M Doses)
- 6.1.2 Global mRNA Vaccines & Therapeutics Sales Market Share by Type (2021-2032)
- 6.2 Global mRNA Vaccines & Therapeutics Revenue by Type (2021-2032)
- 6.2.1 Global mRNA Vaccines & Therapeutics Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global mRNA Vaccines & Therapeutics Revenue Market Share by Type (2021-2032)
- 6.3 Global mRNA Vaccines & Therapeutics Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global mRNA Vaccines & Therapeutics Sales by Application (2021-2032)
- 7.1.1 Global mRNA Vaccines & Therapeutics Sales by Application (2021-2032) & (M Doses)
- 7.1.2 Global mRNA Vaccines & Therapeutics Sales Market Share by Application (2021-2032)
- 7.2 Global mRNA Vaccines & Therapeutics Revenue by Application (2021-2032)
- 7.2.1 Global mRNA Vaccines & Therapeutics Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global mRNA Vaccines & Therapeutics Revenue Market Share by Application (2021-2032)
- 7.3 Global mRNA Vaccines & Therapeutics Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 mRNA Vaccines & Therapeutics Value Chain Analysis
- 8.1.1 mRNA Vaccines & Therapeutics Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 mRNA Vaccines & Therapeutics Production Mode & Process
- 8.2 mRNA Vaccines & Therapeutics Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 mRNA Vaccines & Therapeutics Distributors
- 8.2.3 mRNA Vaccines & Therapeutics Customers
9 Global mRNA Vaccines & Therapeutics Analyzing Market Dynamics
- 9.1 mRNA Vaccines & Therapeutics Industry Trends
- 9.2 mRNA Vaccines & Therapeutics Industry Drivers
- 9.3 mRNA Vaccines & Therapeutics Industry Opportunities and Challenges
- 9.4 mRNA Vaccines & Therapeutics Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst